Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Tumour Registry Colorectal Cancer (TKK)

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2016 by iOMEDICO AG
Arbeitskreis Klinische Studien
Arbeitsgemeinschaft fur Internistische Onkologie
Information provided by (Responsible Party):
iOMEDICO AG Identifier:
First received: May 28, 2009
Last updated: June 27, 2016
Last verified: June 2016

May 28, 2009
June 27, 2016
September 2006
March 2020   (final data collection date for primary outcome measure)
Course of Antineoplastic Treatment [ Time Frame: 5 years ] [ Designated as safety issue: No ]
Course of Antineoplastic Treatment [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT00910819 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Tumour Registry Colorectal Cancer
Prospective and Retrospective Observation of the Adjuvant and Palliative Treatment Strategies in the Therapy of Colorectal Cancer in Germany
To describe treatment reality of patients with colorectal cancer treated by office-based and clinic-based medical oncologists in Germany.

The TKK is a prospective, longitudinal, nation wide cohort study with the purpose to record information on the antineoplastic treatment of colorectal cancer in Germany. The registry will follow patients for up to five years. It will identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics, biomarker testing and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented.

The impact of nutrition (CoNut) and physical activity (CoNut) on the course of the adjuvant disease will be examined, as well as long-term effects of adjuvant treatment (CoTox) and the final phase of the palliative process (CoLife). Based on the available data a prognostic score will be developed.

Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Colorectal cancer patients undergoing antineoplastic treatment.
Colorectal Cancer
Not Provided
Not Provided
Marschner N, Arnold D, Engel E, Hutzschenreuter U, Rauh J, Freier W, Hartmann H, Frank M, Jänicke M. Oxaliplatin-based first-line chemotherapy is associated with improved overall survival compared to first-line treatment with irinotecan-based chemotherapy in patients with metastatic colorectal cancer - Results from a prospective cohort study. Clin Epidemiol. 2015 Apr 20;7:295-303. doi: 10.2147/CLEP.S73857. eCollection 2015.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
March 2020
March 2020   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Colorectal cancer
  • 18 years and older
  • Antineoplastic treatment

Exclusion Criteria:

  • No colorectal cancer
  • Below 18 years
  • No antineoplastic treatment
18 Years and older   (Adult, Senior)
Contact: Natalie Wetzel +49 761 15242 - 0
Contact: Martina Jänicke, PhD +49 761 15242 - 0
Not Provided
  • Arbeitskreis Klinische Studien
  • Arbeitsgemeinschaft fur Internistische Onkologie
Study Chair: Roland Schnell, MD
June 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP